[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=902c56f5529359d9562cd51600b89fd7b327f02d93577e6497997200ad1b692b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741365360,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 133121386,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=902c56f5529359d9562cd51600b89fd7b327f02d93577e6497997200ad1b692b"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Highlights ‘Multi-Billionaire Dollar’ Catalyst for Bristol-Myers Squibb Company (BMY)",
    "summary": "We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other top stocks to watch from Jim Cramer’s latest portfolio. Jim Cramer in a latest program on CNBC said that pain is […]",
    "url": "https://finnhub.io/api/news?id=44a2daf5cf39dc92a2cd5670f88d7ac0b55c62d8c498a4fa8df0c00d833a45ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741360014,
      "headline": "Jim Cramer Highlights ‘Multi-Billionaire Dollar’ Catalyst for Bristol-Myers Squibb Company (BMY)",
      "id": 133185692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other top stocks to watch from Jim Cramer’s latest portfolio. Jim Cramer in a latest program on CNBC said that pain is […]",
      "url": "https://finnhub.io/api/news?id=44a2daf5cf39dc92a2cd5670f88d7ac0b55c62d8c498a4fa8df0c00d833a45ca"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
    "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
    "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741340054,
      "headline": "Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors",
      "id": 133090283,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398811731/image_1398811731.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising for long-term investors.",
      "url": "https://finnhub.io/api/news?id=a2dd56b014439c476c94b99818c078982b06255bce3559661474d82856504139"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer",
    "summary": "By Colin Kellaher Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer....",
    "url": "https://finnhub.io/api/news?id=9bdada69618641b4dda2f8bb830260579aad6081e360d0c6252f85e8d2bc7578",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741332491,
      "headline": "Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer",
      "id": 133086451,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer....",
      "url": "https://finnhub.io/api/news?id=9bdada69618641b4dda2f8bb830260579aad6081e360d0c6252f85e8d2bc7578"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma",
    "summary": "Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared...",
    "url": "https://finnhub.io/api/news?id=c8abf3b8c37bb09fe1c48bb521ac56a61f00193e24b6a987be9ef1af67b1eae6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741330803,
      "headline": "Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma",
      "id": 133086318,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared...",
      "url": "https://finnhub.io/api/news?id=c8abf3b8c37bb09fe1c48bb521ac56a61f00193e24b6a987be9ef1af67b1eae6"
    }
  }
]